Clinical trials: Androgens
Polycystic Ovarian Syndrome (PCOS), Aerobic Exercise
Effects of Aerobic Exercise Training Program in Females With Insulin Resistant Polycystic Ovarian Syndrome
Design: RCT Randomized Clinical Trial Non Probability Convenient Sampling Technique Duration of treatment: 25 weeks 2 groups; (group A=30) SSAET +Normal routine medication+ Normal Dietary Plan , Other group (Group B=30) with…
- Conditions
- Polycystic Ovarian Syndrome (PCOS), Aerobic Exercise, Walking
- Trial name
- SSAET (NCT07157371)
- Testing
- Supervised structured aerobic exercise training, Walk
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Riphah International University
Prostate Neoplasms
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have…
- Trial name
- NCT01715285
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 208 sites in Argentina, Australia and 31 more
- Volunteers
- 1,209 people
- Sponsor
- Janssen Research & Development, LLC
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608450
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 54 sites in United States, Georgia and 1 more
- Volunteers
- 708 people
- Sponsor
- Cassiopea SpA
Prostate Cancer
Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone
The hypothesis of the proposed study would be that, due to the six months of total androgen blockade, which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with…
- Trial name
- PCS III (NCT00223145)
- Testing
- Radiotherapy 70 Gy, Radiotherapy 76 Gy, Androgen blockade
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- Abdenour Nabid
Prostate Cancer
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Oligo-metastatic prostate cancer (OMPCa) is considered as an intermediated state between localized and poly-metastatic disease. Various retrospective studies and prospective clinical trials are carrying out to validate whether…
- Trial name
- NCT05212857
- Testing
- Leuprolide acetate, Goserelin acetate, Triptorelin acetate
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Advanced Prostate Cancer
Study of HPN424 in Patients With Advanced Prostate Cancer
An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy
- Trial name
- NCT03577028
- Testing
- HPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 104 people
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Prostate Cancer
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
RATIONALE: Specialized radiation therapy that delivers a high-dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00528866
- Testing
- bicalutamide, docetaxel, flutamide
- Where
- 70 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
The goal of this clinical research study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery.
- Trial name
- NCT01946165
- Testing
- Abiraterone Acetate, Prednisone, Enzalutamide
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Polycystic Ovary Syndrome, Insulin Resistance
Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS)
Androgen excess is the cardinal biochemical feature of polycystic ovary syndrome (PCOS). Serum testosterone correlates with insulin resistance in PCOS, however, there is an urgent need to improve our understanding of the…
- Conditions
- Polycystic Ovary Syndrome, Insulin Resistance, Androgen; Hypersecretion, Endocrine System Diseases
- Trial name
- DIMOXIS (NCT05263557)
- Testing
- Dehydroepiandrosterone (DHEA), 11-ketoandrostenedione (11KA4)
- Where
- Ireland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Royal College of Surgeons, Ireland
Healthy Men, Male Contraception
Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
The long term objective is to develop a new male hormone 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) as a male hormonal contraceptive.
- Trial name
- CCN014 (NCT02754687)
- Testing
- 11βmethyl nortestosterone dodecylcarbonate
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Premier Research
Prostate Cancer
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side…
- Trial name
- NCT06218667
- Testing
- Copanlisib, Degarelix, Radical Prostatectomy
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy
The Role of 5-alpha Reductase in Mediating Testosterone Actions
In normal men, the male hormone testosterone affects a number of things in the body including muscle function and sexual function.
- Trial name
- 5aR (NCT00493987)
- Testing
- Testosterone Enanthate, Dutasteride
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Prostatic Neoplasms
A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy
Background: Pox viral vectors can induce a PSA-specific T-cell responses and clinical responses in patients with advanced prostate cancer.
- Trial name
- NCT00096551
- Testing
- Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM), Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM), Recombinant Fowlpox-GM-CSF
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional…
- Trial name
- NCT05169112
- Testing
- Lupron Depot
- Where
- 3 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Ottawa Hospital Research Institute
Salivary Gland Cancer
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma.
- Trial name
- NCT05694819
- Testing
- Darolutamide, Goserelin
- Where
- 12 sites in Japan
- Volunteers
- 57 people
- Sponsor
- National Cancer Center Hospital East
Prostate Cancer
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
This study will look at the effect of adding the drug Palbociclib to CAD (Combined Androgen Deprivation) therapy in patients with RB (Retinoblastoma Protein) positive hormone sensitive prostate cancer.
- Trial name
- NCT02059213
- Testing
- Ibrance, Bicalutamide, Zoladex
- Where
- 8 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects…
- Trial name
- NCT07335796
- Testing
- BMS-986165, Degarelix
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Prostate Cancer (PCa) in ADT, Rehabilitation
Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)
This is a drug-free, single arm, single center, superiority, interventional study aimed at treatment feasibility. The main aim of the current study is to assess feasibility of a tailored exercise program as measured by adherence…
- Trial name
- ReCaP (NCT06238596)
- Testing
- rehabilitation
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Prostate Cancer
Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer
Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is overexpressed on prostate cancer cells and is well-characterized as an imaging biomarker of prostate cancer.
- Trial name
- NCT03938766
- Testing
- PSMA PET/CT
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jewish General Hospital
Metastatic Hormone-sensitive Prostate Cancer
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive…
- Trial name
- ARASENS (NCT02799602)
- Testing
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel
- Where
- 322 sites in United States, Australia and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.